Drug firm Bharat Parenterals on Saturday said it has received approval from the Drugs Controller General of India (DCGI) for favipiravir oral suspension, to be used for treatment of COVID-19 patients.
The company has received licence and authorisation from DCGI to manufacture and market favipiravir oral suspension l00mg/ml, Bharat Parenterals said in a regulatory filing.
Favipiravir, an antiviral drug, was approved in Japan in 2014 for the treatment of novel or re-emerging influenza virus infections.
Dharmendra's Apne 2 Not Shelved! Producer Confirms Despite Director Anil Sharma's 'It's Impossible To Make' Comment Amid Actor's Death
‘4 Saal Baad Meeting Sirf Samosa Khane Ke Liye?’: Rajasthan MLA Ravindra Bhati And MP Ummeda Ram Lash Out At IAS Tina Dabi – VIDEO
WPL Auction 2026: Meg Lanning Or Deepti Sharma? UP Warriorz Undecided On Captaincy Despite Spending Spree
Mumbai News: Central Railway’s Alert TTE Busts Fake UTS Season Ticket Racket; Passenger, Husband Booked Under BNS Act
